PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
63.23
-0.47 (-0.74%)
Oct 7, 2026, 4:00 PM EDT - Market closed
PTC Therapeutics Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, PTC Therapeutics stock has a consensus rating of "Buy" and an average price target of $101.79. The average 1-year stock price forecast is 60.98% higher than the current stock price, while the lowest is $70 (+10.71%) and the highest is $137 (+116.67%).
Price Target: $101.79 (+60.98%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for PTC Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 8 | 8 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 3 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 14 | 14 | 14 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $122 | Buy | Maintains | $122 | +92.95% | Oct 7, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $85 | Hold | Maintains | $85 | +34.43% | Oct 7, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $130 → $137 | Buy | Reiterates | $130 → $137 | +116.67% | Sep 22, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $70 → $98 | Buy | Initiates | $70 → $98 | +54.99% | Sep 14, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $109 | Buy | Maintains | $109 | +72.39% | Sep 2, 2026 |
Financial Forecast
Revenue This Year
1.26B
from 1.73B
Decreased by -27.32%
Revenue Next Year
1.38B
from 1.26B
Increased by 9.47%
EPS This Year
1.71
from 7.62
Decreased by -77.57%
EPS Next Year
2.68
from 1.71
Increased by 56.53%
EPS and Forward PE are based on non-GAAP adjusted numbers.